Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study-Reference-Cited by-同舟云学术

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

Published:2011-06 Issue:6 Volume:10 Page:520-529
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Khatri Bhupendra,Barkhof Frederik,Comi Giancarlo,Hartung Hans-Peter,Kappos Ludwig,Montalban Xavier,Pelletier Jean,Stites Tracy,Wu Stacy,Holdbrook Fred,Zhang-Auberson Lixin,Francis Gordon,Cohen Jeffrey A

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference12 articles.

1. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis;Cohen;N Engl J Med,2010

2. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis;Kappos;N Engl J Med,2010

3. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”;Polman;Ann Neurol,2005

4. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS);Kurtzke;Neurology,1983

5. ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1),1996

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depression, anxiety, insomnia and dysmenorrhoea in stressed fingolimod-treated women with multiple sclerosis;The International Journal of Psychiatry in Medicine;2023-07-19

2. The Role of Sphingolipids in Regulating Vascular Permeability in Idiopathic Pulmonary Fibrosis;Biomedicines;2023-06-16

3. Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice;Revue Neurologique;2023-04

4. Lesion location across diagnostic regions in multiple sclerosis;NeuroImage: Clinical;2023

5. Sección III: Tratamiento modificador de la enfermedad en esclerosis múltiple<br>Capítulo 6<br>Fingolimod;Neurología, Neurocirugía y Psiquiatría;2023